Searched for
SPECIALITY PHARMA
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...- Should they now be part of a long-term investing framework? 7 healthcare stocks with upside potential of up to 25%India’s healthcare market may grow steadily, but hospital chains can grow faster as formalisation continues. Healthcare is all about market...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Zydus Lifesciences completes acquisition of AssertioThe company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- India sends measles vaccines, medical supplies to Maldives amid rising casesIndia has provided 20,000 measles vaccine doses and three tonnes of medical supplies to the Maldives. This assistance aims to address incre...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- AI-linked hiring in CDMO industry jumps nearly 3-fold in 2 years: ReportArtificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI s...
- Tata 1mg turns Ebitda positive across core units as diagnostics crosses Rs 600 crore in ARRThe company said its diagnostics business crossed an annualised revenue run rate of more than Rs 600 crore during the year, growing over 40...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equity benchmarks ended lower on Tuesday, snapping a three-session rally amid profit booking in financial, realty and consumer sto...
- Dividends, bonus issues: TCS, LIC, Bajaj Auto among 30 stocks turning ex-date this week. Check detailsInvestors must hold shares of these companies in their demat accounts on the record date to be eligible for the respective corporate action...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Venus Remedies gets Saudi FDA approval for speciality oncology therapyVenus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi ...
- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
Load More
